Gut microbial composition in patients with psoriasis
Por:
Codoñer FM, Ramírez-Bosca A, Climent E, Carrión-Gutierrez M, Guerrero M, Pérez-Orquín JM, Horga J, Genovés S, Ramón D, Navarro-López V and Chenoll E
Publicada:
28 feb 2018
Categoría:
Multidisciplinary
Resumen:
Since the last 5-10 years the relevance of the gut microbiome on different intestinal illnesses has been revealed. Recent findings indicate the effect of gut microbiome on certain dermatological diseases such as atopic dermatitis. However, data on other skin diseases such as psoriasis are limited. This is the first time attempting to reveal the gut microbiome composition of psoriatic patients with a prospective study including a group of patients with plaque psoriasis, analyzing their gut microbiome and the relationship between the microbiome composition and bacterial translocation. The microbiome of a cohort of 52 psoriatic patients (PASI score >= 6) was obtained by 16s rRNA massive sequencing with MiSeq platform (Illumina inc, San Diego) with an average of 85,000 sequences per sample. The study of the gut microbiome and enterotype shows from the first time a specific "psoriatic core intestinal microbiome" that clearly differs from the one present in healthy population. In addition, those psoriatic patients classified as belonging to enterotype 2 tended to experience more frequent bacterial translocation and higher inflammatory status (71%) than patients with other enterotypes (16% for enterotype 1; and 21% for enterotype 3).
Filiaciones:
Codoñer FM:
Lifesequencing S.L.-ADM, Catedrático Agustín Escardino Benlloch 9 Edif 2, 46980, Paterna, Valencia, Spain
Ramírez-Bosca A:
Department of Clinical Medicine, MiBioPath group, Universidad Católica San Antonio de Murcia (UCAM), Guadalupe, Spain
Department of Dermatology, Hospital Universitario del Vinalopó, Elche, Spain
Climent E:
Lifesequencing S.L.-ADM, Catedrático Agustín Escardino Benlloch 9 Edif 2, 46980, Paterna, Valencia, Spain
Carrión-Gutierrez M:
Especialidades Farmacéuticas Centrum, Alicante, Spain
Guerrero M:
Department of Clinical Medicine, MiBioPath group, Universidad Católica San Antonio de Murcia (UCAM), Guadalupe, Spain
Pérez-Orquín JM:
Korott S.L., Carrer Filà Benimerines, 61, 03801, Alcoi, Alicante, Spain
Horga J:
Department of Pharmacology, Pediatrics and Organic Chemistry, Universidad Miguel Hernández de Elche, Alicante, Spain
Genovés S:
Biopolis S.L.-ADM, Catedrático Agustín Escardino Benlloch 9 Edif 2, 46980, Paterna, Valencia, Spain
Ramón D:
Lifesequencing S.L.-ADM, Catedrático Agustín Escardino Benlloch 9 Edif 2, 46980, Paterna, Valencia, Spain
Biopolis S.L.-ADM, Catedrático Agustín Escardino Benlloch 9 Edif 2, 46980, Paterna, Valencia, Spain
:
Department of Clinical Medicine, MiBioPath group, Universidad Católica San Antonio de Murcia (UCAM), Guadalupe, Spain
Infectious Disease Unit, Hospital Universitario del Vinalopó, Elche, Spain
Chenoll E:
Biopolis S.L.-ADM, Catedrático Agustín Escardino Benlloch 9 Edif 2, 46980, Paterna, Valencia, Spain.
Green Published, gold
|